Skip Navigation
Menu
Original Research |1 August 1961

The Treatment of Severe Staphylococcal Infections with Vancomycin

DONALD W. WOODLEY, M.D.; WENDELL H. HALL, M.D., PH.D., F.A.C.P.

FULL TEXT

Abstract

The efficacy of vancomycin (Vancocin®—Lilly) in the treatment of severe staphylococcal infections is becoming well established. According to several authors it is now the agent of choice if the organism is penicillin-resistant (1-3). Vancomycin has a bactericidal action for staphylococci, and as yet no resistant strains have been reported in clinical practice. Toxicity is often bothersome, but it is rarely serious or a cause for discontinuing therapy. A summary of our experience with this drug in 25 cases of serious staphylococcal infections will be presented, along with a review of the literature on vancomycin. The following cases are reported in

FULL TEXT
PDF
Not Available
Citations
Citation

WOODLEY DW, HALL WH. The Treatment of Severe Staphylococcal Infections with Vancomycin. Ann Intern Med. 1961;55:235–249. doi: https://doi.org/10.7326/0003-4819-55-2-235

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 1961;55(2):235-249.

DOI: 10.7326/0003-4819-55-2-235

64 Citations

Related Articles
Annals for Educators - 1 November 2016
Annals of Internal Medicine; 165 (9): ED9
Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence
Annals of Internal Medicine; 165 (2): JC4
Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults
Annals of Internal Medicine; 161 (8): JC9
Review: Fidaxomicin is better than vancomycin for Clostridium difficile recurrence
Annals of Internal Medicine; 156 (8): JC4-9
View MoreView Less

Journal Club
Review: NAATs diagnose C difficile; vancomycin improves cure, and fidaxomicin reduces recurrence
Annals of Internal Medicine; 165 (2): JC4
Weekly dalbavancin was noninferior to daily vancomycin for acute bacterial skin infection in adults
Annals of Internal Medicine; 161 (8): JC9
Review: Fidaxomicin is better than vancomycin for Clostridium difficile recurrence
Annals of Internal Medicine; 156 (8): JC4-9
View MoreView Less

Related Topics
Infectious Disease

Infectious Disease.

PubMed Articles
Advances in the therapy of bacterial bloodstream infections.
Clin Microbiol Infect 2019.
An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes.
Ophthalmol Ther 2019.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×